Stephane Mery
Life Science Investor and Entrepreneur, Non Executive Director
Greater London, England
Overview
Work Experience
Partner
2022 - Current
EverQuest is a leading investment manager in Deep MakeTech (advanced material, processes and design technologies aiming to disrupt most industries' supply chain). The investments apply to the entire value chain from new concepts development to implementation and scale up. The company was set up in partnership with the Center for Process Innovations (CPI) which provides co-investment capabilities, deal flow and technical support.
Director
2022
Occentis, based in Strasbourg, is developing an oral oxytocin analog for Autism, Addiction and Pain; Neurentis which is a partner of Occentis is developing a drug for Refractory Depression (patch), as well as some natural products for mild depression.
Ambassador
2021 - 2023
Following the sales of Contronics to Vesta Software, Vesta has proposed and I accepted that I remain involved with their operations to facilitate further acquisitions.
Non-Executive Director
2015 - 2021
Immupharma is a biotech company, listed on the AIM market, which develops drugs for Lupus and Cancer.
Managing Director
2015 - 2021
Co-owner and MD of Contronics Ltd. Contronics manufactures and sells laboratory monitoring equipments to many blood transfusion centres, hospitals and biotech companies in the UK. The company was sold to Vesta Software in 2021.
Non Executive Director
2015 - 2020
NHSA Ltd is a consortium of the 8 leading universities, 8 NHS Trusts and 4 AHSNs in the North of England to design and develop large projects in life sciences, foster entrepreneurships and attract companies in the region.
Partner
2008 - 2014
In charge of Healthcare investments in Europe
Beringea is a transatlantic venture capital seeking to create lasting success for rapidly scaling entrepreneurial companies
CEO - Fund Manager
2000 - 2008
The BBSF is a seed fund investing into Biotech and Medtech start-up companies from a consortium of universities in London including UCL and CRUK. The fund invested in 10 companies with a few great successes such as Spirogen, that was sold to AstraZeneca/Medimmune for a very large sum.
Director, Business Development
1997 - 2000
As part of the BD team, I licensed a couple of potential blockbusters and out-licensed many compounds.